Group 4 Created with Sketch.
Your changes have been saved

Politics, Science, and Money: The Collective Meltdown over the New Alzheimer’s Drug

Duration: 59:51
In June, the Food and Drug Administration gave marketing approval to the Alzheimer’s drug Aduhelm, against the unanimous advice of its advisory panel. Three of the panel’s five members resigned in protest. The panel’s members and many other medical experts claim there is no convincing evidence that
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of Politics, Science, and Money: The Collective Meltdown over the New Alzheimer’s Drug that people like
There are currently no snippets from Politics, Science, and Money: The Collective Meltdown over the New Alzheimer’s Drug.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for Cato Event Podcast
Playlists that Politics, Science, and Money: The Collective Meltdown over the New Alzheimer’s Drug appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
In June, the Food and Drug Administration gave marketing approval to the Alzheimer’s drug Aduhelm, against the unanimous advice of its advisory panel. Three of the panel’s five members resigned in protest. The panel’s members and many other medical experts claim there is no convincing evidence that the drug provides clinical benefit. Other critics complain that what they see as a useless drug will now cost Medicare (and taxpayers) $56,000 per patient per year.The Aduhelm controversy brings into focus long‐​standing arguments against efficacy requirements for FDA drug approval, especially when the FDA also permits practitioners to prescribe any approved drugs “off label,” deferring to their expertise and clinical judgment. The controversy also directs attention to federal laws that require Medicare to cover most FDA‐​approved drugs and prohibit Medicare from negotiating drug prices.Experts on health care, health and regulatory law, and health economics will explore these and related issues in what promises to be a lively discussion. See acast.com/privacy for privacy and opt-out information.
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications Mark all as read
    You currently have no notifications
    Edit Snippet
    0 / 140
    0 / 140